About Isoaspartyl peptidase/L-asparaginase
Isoaspartyl peptidase/L-asparaginase (ASRGL1) is a protein
from Homo sapiens identified by UniProt accession
Q7L266, 308 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | Isoaspartyl peptidase/L-asparaginase |
|---|
| UniProt accession | Q7L266 |
|---|
| Gene | ASRGL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 308 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (77)
Diseases linked to this target (Open Targets).
- Retinal dystrophy · score 0.37
- serum metabolite measurement · score 0.30
- neuroinflammatory disorder · score 0.24
- CC16 measurement · score 0.21
- chronic obstructive pulmonary disease · score 0.21
- cystatin C measurement · score 0.13
- arterial stiffness measurement · score 0.09
- hepatocellular carcinoma · score 0.08
- BMI-adjusted waist-hip ratio · score 0.08
- axial length measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q7L266-F1 | alphafold | PREDICTED | 94.21 | — |
Amino-acid sequence (308 residues)
MNPIVVVHGG GAGPISKDRK ERVHQGMVRA ATVGYGILRE GGSAVDAVEG AVVALEDDPE FNAGCGSVLN TNGEVEMDAS IMDGKDLSAG AVSAVQCIAN PIKLARLVME KTPHCFLTDQ GAAQFAAAMG VPEIPGEKLV TERNKKRLEK EKHEKGAQKT DCQKNLGTVG AVALDCKGNV AYATSTGGIV NKMVGRVGDS PCLGAGGYAD NDIGAVSTTG HGESILKVNL ARLTLFHIEQ GKTVEEAADL SLGYMKSRVK GLGGLIVVSK TGDWVAKWTS TSMPWAAAKD GKLHFGIDPD DTTITDLP
Explore Isoaspartyl peptidase/L-asparaginase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets